Supplementary Figure 13. Sensitivity analyses in the SU2C cohort upon exclusion of patients who received prior targeted agents.
No takes yet. Share an insight, caveat, or question.
Scalera et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: